Leukemia, Lymphocytic, Chronic, B-Cell
"Leukemia, Lymphocytic, Chronic, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
MeSH Number(s)
C04.557.337.428.080.125
C15.604.515.560.080.125
C20.683.515.528.080.125
Concept/Terms
Leukemia, Lymphocytic, Chronic, B-Cell- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphocytic Lymphoma, Diffuse, Well-Differentiated
- Lymphocytic Lymphoma, Well Differentiated
- Lymphocytic Lymphoma, Well-Differentiated
- Lymphocytic Lymphomas, Well-Differentiated
- Lymphoma, Well-Differentiated Lymphocytic
- Lymphomas, Well-Differentiated Lymphocytic
- Well-Differentiated Lymphocytic Lymphoma
- Well-Differentiated Lymphocytic Lymphomas
- Lymphoma, Lymphocytic
- Lymphoma, Lymphocytic, Diffuse, Well Differentiated
- Lymphoma, Lymphocytic, Diffuse, Well-Differentiated
- Lymphoma, Lymphocytic, Well Differentiated
- Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemias
- Leukemia, Chronic Lymphocytic
- Leukemias, Chronic Lymphocytic
- Lymphocytic Leukemias, Chronic
- Diffuse Well-Differentiated Lymphocytic Lymphoma
- Diffuse Well Differentiated Lymphocytic Lymphoma
- Leukemia, B Cell, Chronic
- Leukemia, B-Cell, Chronic
- Leukemia, Lymphoblastic, Chronic
- Leukemia, Lymphocytic, Chronic
- Leukemia, Lymphocytic, Chronic, B Cell
- Lymphoblastic Leukemia, Chronic
- Chronic Lymphoblastic Leukemia
- Chronic Lymphoblastic Leukemias
- Leukemia, Chronic Lymphoblastic
- Leukemias, Chronic Lymphoblastic
- Lymphoblastic Leukemias, Chronic
- Lymphocytic Leukemia, Chronic
- Lymphocytic Leukemia, Chronic, B Cell
- Lymphocytic Leukemia, Chronic, B-Cell
- Lymphocytic Lymphoma
- Lymphocytic Lymphomas
- Lymphomas, Lymphocytic
- Lymphocytic Lymphoma, Diffuse, Well Differentiated
- Lymphoma, Small Lymphocytic
- Lymphocytic Lymphoma, Small
- Lymphocytic Lymphomas, Small
- Lymphomas, Small Lymphocytic
- Small Lymphocytic Lymphoma
- Small Lymphocytic Lymphomas
- Lymphoma, Small Lymphocytic, Plasmacytoid
- Lymphoma, Small-Cell
- Lymphoma, Small Cell
- Lymphomas, Small-Cell
- Small-Cell Lymphomas
- Lymphoplasmacytoid Lymphoma, CLL
- CLL Lymphoplasmacytoid Lymphoma
- CLL Lymphoplasmacytoid Lymphomas
- Lymphoma, CLL Lymphoplasmacytoid
- Lymphomas, CLL Lymphoplasmacytoid
- Lymphoplasmacytoid Lymphomas, CLL
- Small-Cell Lymphoma
- Small Cell Lymphoma
- B-Cell Chronic Lymphocytic Leukemia
- B Cell Chronic Lymphocytic Leukemia
- B-Cell Leukemia, Chronic
- B Cell Leukemia, Chronic
- B-Cell Leukemias, Chronic
- Chronic B-Cell Leukemia
- Chronic B-Cell Leukemias
- Leukemia, Chronic B-Cell
- Leukemias, Chronic B-Cell
- B-Lymphocytic Leukemia, Chronic
- B Lymphocytic Leukemia, Chronic
- B-Lymphocytic Leukemias, Chronic
- Chronic B-Lymphocytic Leukemia
- Chronic B-Lymphocytic Leukemias
- Leukemia, Chronic B-Lymphocytic
- Leukemias, Chronic B-Lymphocytic
- Lymphoma, Lymphocytic, Well-Differentiated
- Lymphoma, Lymphoplasmacytoid, CLL
Below are MeSH descriptors whose meaning is more general than "Leukemia, Lymphocytic, Chronic, B-Cell".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Lymphoid [C04.557.337.428]
- Leukemia, B-Cell [C04.557.337.428.080]
- Leukemia, Lymphocytic, Chronic, B-Cell [C04.557.337.428.080.125]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Leukemia, Lymphoid [C15.604.515.560]
- Leukemia, B-Cell [C15.604.515.560.080]
- Leukemia, Lymphocytic, Chronic, B-Cell [C15.604.515.560.080.125]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Leukemia, Lymphoid [C20.683.515.528]
- Leukemia, B-Cell [C20.683.515.528.080]
- Leukemia, Lymphocytic, Chronic, B-Cell [C20.683.515.528.080.125]
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Lymphocytic, Chronic, B-Cell".
This graph shows the total number of publications written about "Leukemia, Lymphocytic, Chronic, B-Cell" by people in Harvard Catalyst Profiles by year, and whether "Leukemia, Lymphocytic, Chronic, B-Cell" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 4 | 2 | 6 |
| 1993 | 7 | 1 | 8 |
| 1994 | 7 | 1 | 8 |
| 1995 | 3 | 1 | 4 |
| 1996 | 7 | 0 | 7 |
| 1997 | 8 | 3 | 11 |
| 1998 | 3 | 2 | 5 |
| 1999 | 3 | 2 | 5 |
| 2000 | 4 | 1 | 5 |
| 2001 | 3 | 1 | 4 |
| 2002 | 10 | 1 | 11 |
| 2003 | 3 | 1 | 4 |
| 2004 | 10 | 0 | 10 |
| 2005 | 9 | 4 | 13 |
| 2006 | 12 | 3 | 15 |
| 2007 | 11 | 4 | 15 |
| 2008 | 14 | 7 | 21 |
| 2009 | 9 | 1 | 10 |
| 2010 | 25 | 6 | 31 |
| 2011 | 24 | 3 | 27 |
| 2012 | 22 | 7 | 29 |
| 2013 | 33 | 8 | 41 |
| 2014 | 42 | 1 | 43 |
| 2015 | 39 | 1 | 40 |
| 2016 | 48 | 3 | 51 |
| 2017 | 47 | 2 | 49 |
| 2018 | 42 | 4 | 46 |
| 2019 | 45 | 4 | 49 |
| 2020 | 30 | 3 | 33 |
| 2021 | 56 | 0 | 56 |
| 2022 | 18 | 0 | 18 |
Below are the most recent publications written about "Leukemia, Lymphocytic, Chronic, B-Cell" by people in Profiles.
-
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach. Clin Cancer Res. 2022 Sep 15; 28(18):3958-3964.
-
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022 07 14; 140(2):112-120.
-
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022 08; 23(8):1021-1030.
-
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 08; 23(8):1031-1043.
-
Response to Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients". Haematologica. 2022 06 01; 107(6):1491-1492.
-
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022 06 01; 107(6):1335-1346.
-
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022 06; 20(6):622-634.
-
Idelalisib activates AKT via increased recruitment of PI3Kd/PI3Kß to BCR signalosome while reducing PDK1 in post-therapy CLL cells. Leukemia. 2022 07; 36(7):1806-1817.
-
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood. 2022 04 07; 139(14):2252-2256.
-
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806.